Nehmeh Bilal, Rebehmed Joseph, Nehmeh Riham, Taleb Robin, Akoury Elias
Department of Physical Sciences, Lebanese American University, Beirut 1102-2801, Lebanon.
Department of Computer Science and Mathematics, Lebanese American University, Beirut 1102-2801, Lebanon.
Drug Discov Today. 2024 Dec;29(12):104216. doi: 10.1016/j.drudis.2024.104216. Epub 2024 Oct 18.
Neurodegenerative diseases (NDs) pose serious healthcare challenges with limited therapeutic treatments and high social burdens. The integration of artificial intelligence (AI) into drug discovery has emerged as a promising approach to address these challenges. This review explores the application of AI techniques to unravel therapeutic frontiers for NDs. We examine the current landscape of AI-driven drug discovery and discuss the potentials of AI in accelerating the identification of novel therapeutic targets on ND research and drug development, optimization of drug candidates, and expediating personalized medicine approaches. Finally, we outline future directions and challenges in harnessing AI for the advancement of therapeutics in this critical area by emphasizing the importance of interdisciplinary collaboration and ethical considerations.
神经退行性疾病(NDs)带来了严峻的医疗挑战,治疗手段有限且社会负担沉重。将人工智能(AI)融入药物研发已成为应对这些挑战的一种有前景的方法。本综述探讨了人工智能技术在揭示神经退行性疾病治疗前沿方面的应用。我们审视了当前人工智能驱动的药物研发现状,并讨论了人工智能在加速神经退行性疾病研究和药物开发中新型治疗靶点的识别、候选药物的优化以及推进个性化医疗方法方面的潜力。最后,我们强调跨学科合作和伦理考量的重要性,概述了在利用人工智能推动这一关键领域治疗进展方面的未来方向和挑战。
Biochim Biophys Acta Mol Basis Dis. 2025-3
AAPS PharmSciTech. 2024-8-15
Expert Opin Drug Discov. 2024-8